-
Something wrong with this record ?
Survey of CMV management in pediatric allogeneic HSCT programs, on behalf of the inborn errors, infectious diseases and pediatric diseases working parties of EBMT
T. Bontant, P. Sedlaçek, A. Balduzzi, B. Gaspar, S. Cesaro, H. Einsele, C. Peters, JH. Dalle,
Language English Country England, Great Britain
Document type Journal Article
NLK
Free Medical Journals
from 1997 to 1 year ago
Freely Accessible Science Journals
from 1997 to 1 year ago
ProQuest Central
from 1997-01-01 to 1 year ago
Open Access Digital Library
from 1997-01-01
Medline Complete (EBSCOhost)
from 1997-01-01 to 2015-11-30
Health & Medicine (ProQuest)
from 1997-01-01 to 1 year ago
PubMed
24162611
DOI
10.1038/bmt.2013.164
Knihovny.cz E-resources
- MeSH
- Cytomegalovirus Infections drug therapy therapy MeSH
- Humans MeSH
- Transplantation Conditioning adverse effects methods MeSH
- Surveys and Questionnaires MeSH
- Hematopoietic Stem Cell Transplantation adverse effects methods MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
Human CMV infection is a frequent complication after HSC in children with remarkable morbidity and mortality. Antiviral drugs are relatively efficient but have numerous side effects. They are used as prophylactic, pre-emptive or therapeutic medicines. It is still a matter of debate which option is the best strategy. No uniform procedure has emerged regarding these three options, and new immunologic tools have raised more questions for physicians. To assess the current practice in the management of CMV infection, we sent a questionnaire to the EBMT centers performing hematopoietic SCT (HSCT) in children. Fifty-six out of 196 responded to the questionnaire (28.5%). Quantitative PCR was the most common monitoring tool (44/56). Only 4/56 centers use the pp65 antigenemia alone. All centers used pre-emptive strategy (56/56). 21/56 centers also used prophylactic measures, 13/21 after analysis of donor/receptor serologic status. Ganciclovir was the most common first-line agent for CMV disease (55/56). The most common dose and duration for induction treatment were 5 mg/kg bid (47/55) for 14 days (20/55). There is no uniform procedure for researching resistance strain, antiviral second-line therapy or cell therapy. A harmonization process should enable sound prospective trials to improve prevention, control and cure of CMV disease in children and adolescents.
Chair of EBMT Paediatric Diseases Working Party St Anna Children's Hospital Vienna Austria
Clinica Pediatrica Università degli Studi di Milano Bicocca Ospedale San Gerardo Monza Italy
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc15008534
- 003
- CZ-PrNML
- 005
- 20150313101814.0
- 007
- ta
- 008
- 150306s2014 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1038/bmt.2013.164 $2 doi
- 035 __
- $a (PubMed)24162611
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Bontant, T $u Department of Hematology and Immunology, Hospital Robert Debre, Paris 7-Paris Diderot University, Paris, France.
- 245 10
- $a Survey of CMV management in pediatric allogeneic HSCT programs, on behalf of the inborn errors, infectious diseases and pediatric diseases working parties of EBMT / $c T. Bontant, P. Sedlaçek, A. Balduzzi, B. Gaspar, S. Cesaro, H. Einsele, C. Peters, JH. Dalle,
- 520 9_
- $a Human CMV infection is a frequent complication after HSC in children with remarkable morbidity and mortality. Antiviral drugs are relatively efficient but have numerous side effects. They are used as prophylactic, pre-emptive or therapeutic medicines. It is still a matter of debate which option is the best strategy. No uniform procedure has emerged regarding these three options, and new immunologic tools have raised more questions for physicians. To assess the current practice in the management of CMV infection, we sent a questionnaire to the EBMT centers performing hematopoietic SCT (HSCT) in children. Fifty-six out of 196 responded to the questionnaire (28.5%). Quantitative PCR was the most common monitoring tool (44/56). Only 4/56 centers use the pp65 antigenemia alone. All centers used pre-emptive strategy (56/56). 21/56 centers also used prophylactic measures, 13/21 after analysis of donor/receptor serologic status. Ganciclovir was the most common first-line agent for CMV disease (55/56). The most common dose and duration for induction treatment were 5 mg/kg bid (47/55) for 14 days (20/55). There is no uniform procedure for researching resistance strain, antiviral second-line therapy or cell therapy. A harmonization process should enable sound prospective trials to improve prevention, control and cure of CMV disease in children and adolescents.
- 650 _2
- $a cytomegalovirové infekce $x farmakoterapie $x terapie $7 D003586
- 650 _2
- $a transplantace hematopoetických kmenových buněk $x škodlivé účinky $x metody $7 D018380
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a průzkumy a dotazníky $7 D011795
- 650 _2
- $a příprava pacienta k transplantaci $x škodlivé účinky $x metody $7 D019172
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Sedlaçek, P $u Department of Pediatric Hematology and Oncology, University Hospital Motol, 2nd Medical School, Charles University, Prague, Czech Republic.
- 700 1_
- $a Balduzzi, A $u Clinica Pediatrica Università degli Studi di Milano Bicocca, Ospedale San Gerardo, Monza (Milano), Italy.
- 700 1_
- $a Gaspar, B $u Chair of EBMT Inborn Error Working Party, Molecular Immunology Unit, UCL Institute of Child Health, London, UK.
- 700 1_
- $a Cesaro, S $u Chair of EBMT Infectious Disease Working Party, Paediatric Haematology Oncology Policlinico G.B. Rossi, Verona, Italy.
- 700 1_
- $a Einsele, H $u Division of Hematology, Department of Internal Medicine II, University Hospital of Würzburg, Würzburg, Germany.
- 700 1_
- $a Peters, C $u Chair of EBMT Paediatric Diseases Working Party, St Anna Children's Hospital, Vienna, Austria.
- 700 1_
- $a Dalle, J-H $u Department of Hematology and Immunology, Hospital Robert Debre, Paris 7-Paris Diderot University, Paris, France.
- 773 0_
- $w MED00000834 $t Bone marrow transplantation $x 1476-5365 $g Roč. 49, č. 2 (2014), s. 276-9
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/24162611 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20150306 $b ABA008
- 991 __
- $a 20150313102053 $b ABA008
- 999 __
- $a ok $b bmc $g 1065807 $s 891334
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2014 $b 49 $c 2 $d 276-9 $i 1476-5365 $m Bone marrow transplantation $n Bone Marrow Transplant $x MED00000834
- LZP __
- $a Pubmed-20150306
